Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Japan A 71-year-old male patient with adenocarcinoma of the lung and contralateral lung metastasis under administration of pembrolizumab had symptoms of cerebellar ataxia. We suspected that the ...

CHICAGO — In patients with stage IVB anaplastic thyroid cancer, the inclusion of adjuvant pembrolizumab to conventional multimodal therapy shows significant benefits in reducing the recurrence ...

In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received pembrolizumab developed immune-related adverse events — findings that ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

At a median follow-up of 29.9 months (range, 12.8-43.0), significant differences in overall survival (OS) were observed between the pembrolizumab plus chemoradiotherapy group and the chemoradiotherapy ...

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer. Ivonescimab reduced the risk of ...

Immune checkpoint inhibitor-related diabetes mellitus (ICI-DM) is a rare complication that medical oncologists seldom encounter in routine practice. The sporadic nature and intrinsic complexity of ICI ...